Annual Cash & Cash Equivalents
$6.08 B
+$673.00 M+12.44%
31 December 2023
Summary:
Gilead Sciences annual cash & cash equivalents is currently $6.08 billion, with the most recent change of +$673.00 million (+12.44%) on 31 December 2023. During the last 3 years, it has risen by +$88.00 million (+1.47%). GILD annual cash & cash equivalents is now -66.08% below its all-time high of $17.94 billion, reached on 31 December 2018.GILD Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$5.04 B
+$2.27 B+81.71%
30 September 2024
Summary:
Gilead Sciences quarterly cash and cash equivalents is currently $5.04 billion, with the most recent change of +$2.27 billion (+81.71%) on 30 September 2024. Over the past year, it has dropped by -$668.00 million (-11.71%). GILD quarterly cash and cash equivalents is now -71.92% below its all-time high of $17.94 billion, reached on 31 December 2018.GILD Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GILD Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +12.4% | -11.7% |
| 3 y3 years | +1.5% | +15.5% |
| 5 y5 years | -66.1% | -46.8% |
GILD Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +14.0% | -17.2% | +81.7% |
| 5 y | 5 years | -66.1% | +14.0% | -60.9% | +81.7% |
| alltime | all time | -66.1% | >+9999.0% | -71.9% | >+9999.0% |
Gilead Sciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $5.04 B(+81.7%) |
| June 2024 | - | $2.77 B(-41.2%) |
| Mar 2024 | - | $4.72 B(-22.5%) |
| Dec 2023 | $6.08 B(+12.4%) | $6.08 B(+6.7%) |
| Sept 2023 | - | $5.71 B(+0.0%) |
| June 2023 | - | $5.70 B(+15.6%) |
| Mar 2023 | - | $4.94 B(-8.8%) |
| Dec 2022 | $5.41 B(+1.4%) | $5.41 B(+15.2%) |
| Sept 2022 | - | $4.70 B(-0.8%) |
| June 2022 | - | $4.74 B(+10.3%) |
| Mar 2022 | - | $4.30 B(-19.5%) |
| Dec 2021 | $5.34 B(-11.0%) | $5.34 B(+22.4%) |
| Sept 2021 | - | $4.36 B(-10.9%) |
| June 2021 | - | $4.89 B(+20.4%) |
| Mar 2021 | - | $4.07 B(-32.2%) |
| Dec 2020 | $6.00 B(-48.4%) | $6.00 B(-53.5%) |
| Sept 2020 | - | $12.89 B(+91.0%) |
| June 2020 | - | $6.75 B(-32.9%) |
| Mar 2020 | - | $10.05 B(-13.6%) |
| Dec 2019 | $11.63 B(-35.2%) | $11.63 B(+22.8%) |
| Sept 2019 | - | $9.47 B(-15.7%) |
| June 2019 | - | $11.24 B(-33.6%) |
| Mar 2019 | - | $16.93 B(-5.6%) |
| Dec 2018 | $17.94 B(+136.4%) | $17.94 B(+23.1%) |
| Sept 2018 | - | $14.57 B(+10.1%) |
| June 2018 | - | $13.23 B(+73.2%) |
| Mar 2018 | - | $7.64 B(+0.7%) |
| Dec 2017 | $7.59 B(-7.8%) | $7.59 B(-34.1%) |
| Sept 2017 | - | $11.51 B(+32.1%) |
| June 2017 | - | $8.71 B(-15.3%) |
| Mar 2017 | - | $10.29 B(+25.0%) |
| Dec 2016 | $8.23 B(-36.0%) | $8.23 B(-16.1%) |
| Sept 2016 | - | $9.81 B(+51.3%) |
| June 2016 | - | $6.49 B(+2.7%) |
| Mar 2016 | - | $6.32 B(-50.9%) |
| Dec 2015 | $12.85 B(+28.2%) | $12.85 B(-8.0%) |
| Sept 2015 | - | $13.96 B(+88.3%) |
| June 2015 | - | $7.42 B(-30.3%) |
| Mar 2015 | - | $10.63 B(+6.1%) |
| Dec 2014 | $10.03 B(+374.5%) | $10.03 B(+61.5%) |
| Sept 2014 | - | $6.21 B(-28.9%) |
| June 2014 | - | $8.73 B(+36.3%) |
| Mar 2014 | - | $6.40 B(+203.1%) |
| Dec 2013 | $2.11 B(+17.1%) | $2.11 B(+5.1%) |
| Sept 2013 | - | $2.01 B(-8.7%) |
| June 2013 | - | $2.20 B(+18.1%) |
| Mar 2013 | - | $1.86 B(+3.3%) |
| Dec 2012 | $1.80 B(-81.8%) | $1.80 B(+16.3%) |
| Sept 2012 | - | $1.55 B(-4.6%) |
| June 2012 | - | $1.63 B(+12.0%) |
| Mar 2012 | - | $1.45 B(-85.3%) |
| Dec 2011 | $9.88 B(+988.7%) | $9.88 B(+986.9%) |
| Sept 2011 | - | $909.36 M(+0.4%) |
| June 2011 | - | $905.78 M(-50.7%) |
| Mar 2011 | - | $1.84 B(+102.2%) |
| Dec 2010 | $907.88 M(-28.7%) | $907.88 M(-11.3%) |
| Sept 2010 | - | $1.02 B(-31.0%) |
| June 2010 | - | $1.48 B(+58.3%) |
| Mar 2010 | - | $936.88 M(-26.4%) |
| Dec 2009 | $1.27 B(-12.8%) | $1.27 B(+24.2%) |
| Sept 2009 | - | $1.02 B(-1.6%) |
| June 2009 | - | $1.04 B(-37.4%) |
| Mar 2009 | - | $1.66 B(+14.0%) |
| Dec 2008 | $1.46 B | $1.46 B(+20.7%) |
| Sept 2008 | - | $1.21 B(+8.0%) |
| June 2008 | - | $1.12 B(+54.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $722.88 M(-25.3%) |
| Dec 2007 | $968.09 M(+18.6%) | $968.09 M(+65.7%) |
| Sept 2007 | - | $584.13 M(-16.7%) |
| June 2007 | - | $701.65 M(-3.8%) |
| Mar 2007 | - | $729.14 M(-10.6%) |
| Dec 2006 | $816.01 M(+15.3%) | $816.01 M(+45.8%) |
| Sept 2006 | - | $559.58 M(-36.7%) |
| June 2006 | - | $884.45 M(+229.2%) |
| Mar 2006 | - | $268.68 M(-62.0%) |
| Dec 2005 | $707.91 M(+152.0%) | $707.91 M(+19.4%) |
| Sept 2005 | - | $592.72 M(-25.3%) |
| June 2005 | - | $793.62 M(+181.5%) |
| Mar 2005 | - | $281.94 M(+0.4%) |
| Dec 2004 | $280.91 M(+44.3%) | $280.91 M(-6.8%) |
| Sept 2004 | - | $301.45 M(+33.1%) |
| June 2004 | - | $226.56 M(+45.6%) |
| Mar 2004 | - | $155.59 M(-20.1%) |
| Dec 2003 | $194.72 M(-68.4%) | $194.72 M(+88.5%) |
| Sept 2003 | - | $103.32 M(-39.0%) |
| June 2003 | - | $169.35 M(+44.2%) |
| Mar 2003 | - | $117.48 M(-81.0%) |
| Dec 2002 | $616.93 M(+399.6%) | $616.93 M(+407.3%) |
| Sept 2002 | - | $121.61 M(-0.3%) |
| June 2002 | - | $122.01 M(+6.0%) |
| Mar 2002 | - | $115.09 M(-6.8%) |
| Dec 2001 | $123.49 M(-37.4%) | $123.49 M(+230.7%) |
| Sept 2001 | - | $37.35 M(-20.4%) |
| June 2001 | - | $46.92 M(-39.4%) |
| Mar 2001 | - | $77.40 M(-60.8%) |
| Dec 2000 | $197.29 M(+319.7%) | $197.29 M(+354.9%) |
| Sept 2000 | - | $43.37 M(+1.5%) |
| June 2000 | - | $42.74 M(+14.6%) |
| Mar 2000 | - | $37.30 M(-20.7%) |
| Dec 1999 | $47.01 M(-53.5%) | $47.01 M(-33.6%) |
| Sept 1999 | - | $70.80 M(+56.3%) |
| June 1999 | - | $45.30 M(-22.4%) |
| Mar 1999 | - | $58.40 M(-42.2%) |
| Dec 1998 | $101.10 M(+215.9%) | $101.10 M(+134.0%) |
| Sept 1998 | - | $43.20 M(+16.8%) |
| June 1998 | - | $37.00 M(+7.9%) |
| Mar 1998 | - | $34.30 M(+7.2%) |
| Dec 1997 | $32.00 M(-75.8%) | $32.00 M(-30.0%) |
| Sept 1997 | - | $45.70 M(-67.1%) |
| June 1997 | - | $139.00 M(+32.8%) |
| Mar 1997 | - | $104.70 M(-20.7%) |
| Dec 1996 | $132.00 M(+381.8%) | $132.00 M(-15.4%) |
| Sept 1996 | - | $156.00 M(-14.7%) |
| June 1996 | - | $182.90 M(+270.2%) |
| Mar 1996 | - | $49.40 M(-31.8%) |
| Dec 1995 | $27.40 M(-9.9%) | - |
| Sept 1995 | - | $72.40 M(+751.8%) |
| June 1995 | - | $8.50 M(-72.0%) |
| Mar 1995 | - | $30.40 M(+98.7%) |
| Mar 1995 | $30.40 M(+133.8%) | - |
| Dec 1994 | - | $15.30 M(-42.5%) |
| Sept 1994 | - | $26.60 M(-39.1%) |
| June 1994 | - | $43.70 M(+236.2%) |
| Mar 1994 | $13.00 M(+519.0%) | $13.00 M(+51.2%) |
| Dec 1993 | - | $8.60 M(+309.5%) |
| Sept 1993 | - | $2.10 M(-40.0%) |
| June 1993 | - | $3.50 M(+66.7%) |
| Mar 1993 | $2.10 M(-97.6%) | $2.10 M(-95.6%) |
| Dec 1992 | - | $47.80 M(+1978.3%) |
| Sept 1992 | - | $2.30 M(-87.2%) |
| June 1992 | - | $17.90 M(-79.6%) |
| Mar 1992 | $87.90 M(+753.4%) | $87.90 M(+753.4%) |
| Mar 1991 | $10.30 M | $10.30 M |
FAQ
- What is Gilead Sciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Gilead Sciences?
- What is Gilead Sciences annual cash & cash equivalents year-on-year change?
- What is Gilead Sciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Gilead Sciences?
- What is Gilead Sciences quarterly cash and cash equivalents year-on-year change?
What is Gilead Sciences annual cash & cash equivalents?
The current annual cash & cash equivalents of GILD is $6.08 B
What is the all time high annual cash & cash equivalents for Gilead Sciences?
Gilead Sciences all-time high annual cash & cash equivalents is $17.94 B
What is Gilead Sciences annual cash & cash equivalents year-on-year change?
Over the past year, GILD annual cash & cash equivalents has changed by +$673.00 M (+12.44%)
What is Gilead Sciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of GILD is $5.04 B
What is the all time high quarterly cash and cash equivalents for Gilead Sciences?
Gilead Sciences all-time high quarterly cash and cash equivalents is $17.94 B
What is Gilead Sciences quarterly cash and cash equivalents year-on-year change?
Over the past year, GILD quarterly cash and cash equivalents has changed by -$668.00 M (-11.71%)